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There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective
effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying
effects in Parkinson’s disease (PD) for over 20 years in various clinical trials. This review provides a summary of the
clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier
clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline
using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims
of this strategy remain elusive due to obstacles, some of which may be insurmountable.
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For the purposes of this review, the term “disease-modi-
fication” refers to a broad definition of therapies which
can slow or favorably modify the progressive degenera-
tive processes in dopaminergic and non-dopaminergic
neurons associated with Parkinson’s disease (PD). In this
context, the term “neuroprotection” has been used almost
synonymously with “disease-modification”. Monoamine
oxidase-B (MAOB) is an enzyme that is involved in dopa-
mine metabolism (Figure 1). MAOB inhibitors, namely
selegiline and rasagiline, have been studied extensively for
disease-modification in PD. This review will cover the
rationale of this therapeutic strategy, clinical trials on
MAOB inhibitors, the debates and caveats of the conclu-
sions of these studies, and discuss the issues in deciding
whether newer monoamine oxidase-B inhibitors such as
rasagiline should be prescribed in the context of disease-
modification in PD.
The incidence of PD increases with age, and is associ-
ated with significant disability. Its prevalence in patients* Correspondence: slho@hku.hk
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reproduction in any medium, provided the orover 50 years of age is projected to double in the ten most
populous nations over the next two decades [1]. Classical
motor features of PD such as bradykinesia, rigidity and
tremor develop when about 50% of dopaminergic nigros-
triatal neurons and about 80% striatal dopamine produc-
tion are lost [2]. However, non-dopaminergic neurons
pathways also undergo degeneration in PD, including cho-
linergic, noradrenergic, serotonergic and GABAergic path-
ways, resulting in a variety of non-motor features such as
dementia, psychosis, depression and apathy. Unlike motor
features which respond well to dopaminergic therapies
such as levodopa and dopamine agonists, non-motor fea-
tures which have either no or little response to dopamin-
ergic therapies, can be more disabling to the patient and
have a far greater impact on the quality of life. As yet,
there is no conclusive proof that current therapy can
delay, halt or reverse the neuronal degeneration in PD.
Existing drug treatment is associated with a gradual loss
of efficacy and long term side effects. Although stereotac-
tic deep brain stimulation can relieve some motor symp-
toms, other motor and non-dopaminergic features are not
relieved. As symptom-onset in most PD patients occur in
their early 60s, even if partial disease-modification can be
achieved, the progression to severe disability may beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Dopamine metabolism and the action of monoamine oxidase. Abbreviations: VMAT2, vesicular monoamine transporter 2; DAT,
dopamine active transporter; DOPAC, 3,4-dihydroxyphenylacetic acid; 3MT, 3-methoxytyramine; HVA, homovanillic acid.
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provide them with a satisfactory quality of life.
Selegiline
Selegiline (N-Propargyl-methamphetamine) is a selective, ir-
reversible MAOB inhibitor at therapeutic dose of 10 mg/day,
but loses its selectivity at greater dosage [3]. Hence,
selegiline at therapeutic dose does not cause the “cheese”
reaction. The potential of selegiline to modify disease
progression in PD was first proposed when it was shown
to prevent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced parkinsonism in monkeys [4]. Invitro
and invivo experiments have reported neuroprotective
properties of selegiline [4-11]. Selegiline is a derivative of
methamphetamine and is metabolized to L-amphetamine-
like metabolites which can cause sympathomimetic side
effects such as insomnia [12].
Selegiline as monotherapy or an adjunct to levodopa
Selegiline monotherapy was shown to provide modest
symptomatic benefit and delay the need of levodopa
therapy in early PD [13-15]. As an adjunct to levodopa
therapy, selegiline can reduce motor fluctuations [15].
Deprenyl and Tocopherol Antioxidative Therapy of
Parkinsonism (DATATOP) was the largest prospective con-
trolled trial ever done for Selegiline [13]. The DATATOPstudy was initially designed to evaluate the neuroprotective
properties of selegiline and tocopherol. Eight hundred
untreated de novo PD patients were randomly assigned
according to a 2x2 factorial design to one of the four treat-
ment arms: selegiline placebo and alpha-tocopherol pla-
cebo; selegiline 10mg/day and alpha-tocopherol 2000 IU/
day; selegiline 10mg/day; and alpha-tocopherol 2000 IU/
day. Unified Parkinson’s Disease Rating Scale (UPDRS)
were evaluated at 1 month and 3 months after random-
ization, then approximately 3 monthly for a planned max-
imum of 2 years. The primary end point was reached when
subjects developed a level of functional disability which re-
quired levodopa therapy. There was significant improve-
ment of UPDRS score in the subjects who received
selegiline during the 3 months “wash in” period indicating
an early symptomatic benefit of selegiline. Selegiline delayed
the need of levodopa by approximately 9 months. The
Kaplan-Meier analysis showed that taking selegiline sig-
nificantly reduced the probability of having to start levo-
dopa therapy during the study period (hazard ratio 0.50;
95% confidence interval 0.41 to 0.62, p<0.001). However,
after a “wash out” period in subjects who did not reach
the end point, there was a significant deterioration of the
UPDRS score, indicating a symptomatic effect of sele-
giline. This symptomatic effect was not factored in during
the initial study design. The results of DATATOP are
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the symptomatic effects of selegiline.
Further evidence supporting the role of selegiline in the
treatment of PD came from another multicentered, ran-
domized, placebo-controlled, double-blinded study, involv-
ing 157 patients, who were randomly assigned to receive
either selegiline 10mg/day or placebo [14]. The primary
end point was reached when initiation of levodopa therapy
became necessary. At 3 months follow up, the selegiline
group had significant improvement of UPDRS total score
(−1.7±5.4 vs. 1.0±5.3, p<0.01), Visual Analogue Scale
(VAS) tremor score (−4.0±18.4 vs. 4.0±16.9, p<0.05) and
VAS motor dysfunction score (−3.0±21.3 vs. 6.8±19.6,
p<0.05), when compared to the placebo group. The
need for levodopa was delayed by 4.1 months with
selegiline (p=0.028). In their follow up study up to 7 years
involving 141 patients, either selegiline or placebo was
restarted in addition to levodopa therapy after an initial
8 weeks “wash out” period [16]. The selegiline group had
slower disease deterioration as measured by the UPDRS
total score (p=0.003), motor (p=0.002) and ADL (p=0.0002)
subscores. Considering both the initial monotherapy and
subsequent combination therapy up to 7 years, selegiline
did not delay the start on wearing off fluctuations (hazard
ratio 0.55; 95% confidence interval: 0.28 to 1.07, p=0.076).
A recent systemic review supported the early symptom-
atic and long term benefit of selegiline [15]. Selegiline was
shown to be beneficial compared to control in motor im-
pairment in 4 randomized control trials (RCTs) involving
986 patients. The weighted mean difference (WMD) for
the change in motor UPDRS score was −4.49 (95% confi-
dence interval: -5.52 to −3.46) and WMD in UPDRS ADL
score was −2.19 (95% confidence interval: -2.78 to −1.60)
at 1 year. Motor fluctuations were significantly reduced
with selegiline (6 RCTs involving 1461 patients, odds ratio
0.73; 95% confidence interval: 0.58 to 0.91) at a mean
weighted duration of follow up of 3.4 years. There was no
significant difference in death or dyskinesia over the con-
trol subjects.
Selegiline in clinical trials for disease-modification in PD
There is no conclusive evidence from clinical trials to
prove that selegiline has “disease-modification” effects,
even though it was shown to have neuroprotective prop-
erties in invitro and invivo experimental models [4-11].
Long term clinical trials of selegiline have shown im-
proved motor outcome and reduced levodopa require-
ment [16-19]. Whether these findings were attributed to
the symptomatic benefits or the disease-modification
property of selegiline remain debatable. Unlike rasagiline
in which delayed-start design trials were carried out in
an attempt to separate confounding symptomatic effects
from disease-modifying effects, there are none for selegiline
(discussed in more detail below).Lazabemide
Lazabemide (N-(2-aminoethyl)-5-chloro-2-pyridinecarboxa-
mide) was first tested in clinical trials for treatment of PD
in the 1990s. Lazabemide is a more selective inhibitor of
MAOB when compared to selegiline. Unlike selegiline, it
is not metabolized to L-amphetamine-like metabolites and
has a shorter “wash out” period [20]. The shorter “wash
out” period of lazabemide was thought to provide a better
assessment of the disease-modifying effects, as the change
in PD status between baseline and post-treatment after a
“wash out” period may not be confounded by any persist-
ent symptomatic effect [21]. The disease-modifying effects
of lazabemide was assessed in a randomized controlled
trial which involved 321 de novo early PD patients [21].
Patients were randomly assigned to receive either placebo
or lazabemide 25 to 200mg/day with a 2 to 4 week “wash
out” period. Similar to selegiline, lazabemide was found to
have a mild symptomatic effect. The probability of
reaching disability sufficient to need initiation of levodopa
therapy was significant reduced in lazabemide-treated pa-
tients (hazard ratio 0.49; 95% confidence interval 0.32 to
0.77; p=0.001). After the “wash out” period, lazabemide-
treated patients had a slower deterioration of PD impair-
ment as evidenced by a lesser decline in total UPDRS
score when compared to placebo (− 6.1±8.4 vs. – 8.1±8.5;
p=0.06), indicating a possible disease-modifying effect.
However, its manufacturer decided to halt further de-
velopment of lazabemide in 1999 after reporting liver
toxicity [22].
Rasagiline
Rasagiline (N-propargyl-1-(R)-aminoindan) is a second
generation propargylamine-based selective, irreversible
MAOB inhibitor. It was reported to have potent anti-
apoptotic effects independent of MAO inhibition in
invitro and invivo experimental parkinsonian models
[23-25]. It can cross the blood–brain-barrier readily
[26]. Similar to selegiline, rasagiline lacks dietary tyram-
ine sympathomimetic potentiation at its MAOB inhibi-
tory dosage [23,27], and hence, lacks the undesirable
pressor effects of the “cheese” reaction associated with
MAOA inhibition. Unlike selegiline, rasagiline is not
metabolized to L-amphetamine-like metabolites which
may cause appetite suppression and insomnia [24].
Rasagiline as an adjunct therapy to levodopa for motor
fluctuations in PD
Rasagiline was tested as an adjunct therapy to levodopa
in alleviating parkinsonian motor fluctuations in two
separate multicentered, double-blind, parallel-group clin-
ical trials: a) PRESTO (Parkinson’s Rasagiline: Efficacy and
Safety in the Treatment of “Off”) [28] and b) LARGO
(Lasting effect in Adjunct therapy with Rasagiline Given
Once daily) studies [29].
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2½ hours of daily “off” time were randomized to receive
rasagiline (in either 1 mg/day or 0.5 mg/day) or placebo,
as an adjunct therapy to levodopa over 26 weeks [28]. In
its primary outcome measure, the mean adjusted total
daily “off” time as measured by patients’ home diaries
had a modest but statistically significant reduction from
baseline by 1.85 hours (29%) in patients treated with
1 mg/day dose, by 1.41 hours (23%) with 0.5 mg/day
dose, and 0.91 hours (15%) with placebo. Patients had
0.94 hours and 0.49 hours less “off” time on 1 mg/day
and 0.5 mg/day doses respectively, compared to placebo.
The changes on activities of daily living (ADL) and qual-
ity of life were less consistent. The Clinical Global Im-
pression (CGI) and the UPDRS ADL scores during “off”
time showed improvement as secondary end points with
both doses of rasagiline, but not with PDQUALIF (PD
Quality of Life) summary score.
In the LARGO study, 687 PD patients with at least 1
hour of “off” time during awake hours as measured by
24-hour patients’ home diaries, were randomized to re-
ceive either rasagiline (1 mg/day), entacapone (200 mg
with each dose of levodopa) or placebo, as an adjunct
therapy to levodopa for 18 weeks [29]. In its primary
outcome measure, patients who had received rasagiline
had a statistically significant reduction of mean daily
“off” time by 1.18 hours; those on entacapone by 1.2 hours
(both about 20%), and placebo by 0.4 hours from base-
line. The mean daily “on” time without troublesome
dyskinesia had a modest but statistically significant in-
crease of 0.85 hours in those patients who received
rasagiline compared with 0.03 hours who received
placebo; the improvement was similar in magnitude
to entacapone. The CGI and UPDRS ADL scores dur-
ing “off” time significantly improved in those patients
taking rasagiline compared to placebo, comparable to
entacapone.
In both the PRESTO and LARGO trials, rasagiline was
well-tolerated. The adverse events which included nau-
sea, anorexia and postural hypotension were mild.
Rasagiline did not have any significant effects on the
pulse or blood pressure.
Rasagiline in clinical trials for disease-modification in PD
Apart from its effects on the motor symptoms of PD,
rasagiline was tested for its neuroprotective effects in two
prospective, double-blind, placebo-controlled, parallel-
group, randomized clinical studies on patients with early
PD: a) TEMPO (TVP-1012 in Early Monotherapy for PD
Outpatients) [30,31], and b) ADAGIO (Attenuation of
Disease Progression with Azilect Given Once-daily) stud-
ies [32]. Patients with early stages of untreated PD were
chosen because of the concern that the pathogenic pro-
cesses and neuronal cell death would have been too faradvanced in the late stages of PD for disease-modification
to make any clinically meaningful impact. Another major
concern raised after the conclusion of the DATATOP
study and the subsequent studies on selegiline, was the
confounding effects of symptomatic improvement on the
assessment of disease-modifying benefits of the drug [13].
Both TEMPO and ADAGIO studies used a delayed-start
design in an attempt to separate confounding symptomatic
from disease-modifying effects [30-32]. The design essen-
tially divided the trial period into two phases. The treat-
ment groups would be randomized in the first phase to
either placebo or rasagiline treatment arms. The first phase
would have to be sufficiently long to allow any disease-
modifying effects of rasagiline more opportunity to mani-
fest. This initial phase would be followed by a second
phase where all the groups would receive rasagiline but
the initial randomization was kept blinded. As all the treat-
ment arms received rasagiline during the second phase of
the study, any confounding symptomatic effects between
the different arms at the end of the study would be
negated. Hence, any differences in outcome would pre-
sumably be due to disease-modifying effects of rasagiline
from the delayed start of rasagiline during the first phase
of the study.
In the TEMPO study, 404 early PD patients who did not
require dopaminergic therapy were randomized to three
parallel arms: 1 mg/day or 2 mg/day for 12 months, or
placebo for the first 6 months followed by rasagiline
2 mg/day for another 6 months [30,31]. In its analysis
based on the primary outcome measure over the first
6 month trial period, the total UPDRS score (adjusted
for effect size) worsened significantly less compared to
placebo from baseline; by 4.2 points less than placebo
(95% confidence interval: 5.66 to 2.73 points, p<0.001)
in patients who received rasagiline 1 mg/day, and by
3.56 points less than placebo (95% confidence interval:
5.04 to 2.08 points, p<0.001) in patients who received
2 mg/day dose [30]. The improvement observed was
similar between the two doses of rasagiline over this ini-
tial 6 month period. Although there are no direct com-
parisons as yet, the symptomatic effects of rasagiline
monotherapy in early PD appear to be more modest
than dopamine agonists. In a later analysis performed in
the same study, patients who received rasagiline 1 mg/day
over 12 months had less worsening of mean adjusted total
UPDRS score of 1.82 points (95% confidence interval: 3.64
to 0.01 points, p=0.05) compared with the delayed start
rasagiline 2 mg/day [31]. Patients who received rasagiline
2 mg/day over 12 months had even less worsening of
mean adjusted total UPDRS score of 2.29 points (95%
confidence interval: 4.11 to 0.48 points, p=0.01) compared
with the delayed start rasagiline 2 mg/day. The study con-
cluded that rasagiline at either 1 mg/day or 2 mg/day had
less functional decline compared with the delayed start
Teo and Ho Translational Neurodegeneration 2013, 2:19 Page 5 of 10
http://www.translationalneurodegeneration.com/content/2/1/19group. These studies raised the possibility that early-start
rasagiline appeared to have enduring benefits over delayed-
start, but it also raised concerns [33]. In an open-labeled ex-
tension the TEMPO study, 306 patients who continued on
rasagiline were followed up to 6½ years (mean±SD: 3.6±
2.1 years) [34]. The adjusted mean difference in change
from baseline in total UPDRS scores was 2.5 points (16%)
in favor of early-start compared to delayed-start. This ex-
tension study also reported that although the interaction
between treatment and time was significant, there was sig-
nificantly less worsening in total UPDRS scores in the
early-start compared to the delayed-start group at all
seven half-yearly follow up time points.
The ADAGIO study which was larger and longer, but
with a similar delayed-start design on rasagiline soon
followed [35]. It involved 1,176 patients with early, un-
treated PD randomized in four parallel arms: rasagiline
at either 1 mg/day or 2 mg/day for a total of 72 weeks
(early-start group), and placebo for 36 weeks followed
rasagiline at either 1 mg/day or 2 mg/day for another
36 weeks (delayed-start group). In order for the study to
indicate significant disease-modification, the early-start
group had to meet each of three hierarchical ends points
of the primary analysis based on the total UPDRS score:
a) superiority to placebo in the rate of change of the
UPDRS score between weeks 12 and 36 during the first
phase of the study, b) superiority to delayed-start treat-
ment in the change of the score from baseline to week
72, and c) non-inferiority to delayed-start treatment in
the rate of change of the score between weeks 48 and 72
during the second phase of the study. The results showed
that rasagiline 1mg/day dose achieved all three hier-
archical primary endpoints based on disease progression: a)
a slower mean rate of worsening in total UPDRS score be-
tween weeks 12 and 36 compared to placebo (0.09 points/
week in early-start treatment versus 0.14 points/week in
placebo group), b) less worsening of mean total UPDRS
score from baseline to week 72 in early-start (2.82 points)
compared delayed-start (4.52 points) treatment, c) non-
inferiority of the early-start treatment in the mean rate of
change of the total UPDRS score between weeks 48 and
72 in early-start (0.085 points/week) compared with
delayed-start (0.085 points/week) treatment. However, the
2mg/day dose failed to achieve all its primary endpoints
because the change of mean total UPDRS score from
baseline to week 72 in the early-start (3.47 points) was not
significantly different from the delay-start treatment (3.11
points). However, the early-start treatment group taking
rasagiline 2 mg/day dose had less mean rate of worsening
(0.07 points/week) in total UPDRS score compared with
placebo (0.14 points/week) between weeks 12 to 36. Fur-
thermore, at the 2 mg/day dose, the mean rate of change in
total UPDRS between weeks 48 to 72 in the early-start
(0.094 points/week) was non-inferior to delayed-starttreatment (0.065 points/week). Nevertheless, the result of
the 2 mg/day dose was considered to be negative because
the design was such that all three hierarchical primary
endpoints had to be met for each separate dose. The
authors concluded that early-start treatment rasagiline at
1 mg/day provided benefits consistent with possible
disease-modifying effects even though it did not met its
endpoints at 2 mg/day.
The ADAGIO study results raised some debate and
concerns, in particular, the divergent and paradoxical
outcome between 1 mg/day and 2 mg/day doses [36,37].
It is unknown how PD progresses and whether it does
so linearly. It was also unclear whether confounding
symptomatic effects of rasagiline were significantly ne-
gated. The first hierarchical endpoint of superiority to
placebo in the rate of change of the total UPDRS score
between weeks 12 and 36 relied on the assumptions that,
a) the rate of change of this score was linear during this
period; and b) the symptomatic effects of rasagiline were
fully established by week 12 [35]. This linearity from
weeks 12 to 36 and whether the confounding symptom-
atic effects were fully established before the assessments
on the first endpoint, have been disputed [36], and ques-
tions raised on whether the rasagiline 1 mg/day dose
had met the pre-specified criteria. The authors of the
ADAGIO trial argued that there are many pharmaco-
logical examples where dose-related efficacy may not
occur but it was thought that the doubling of the
rasagiline dose was unlikely to have a U or J curve effect
[38,39]. The authors of the ADAGIO trial also noted
that their posthoc analysis of the subgroup of patients
with the highest total UPDRS score at baseline (i.e., the
most severely affected quartile) had met all its primary
endpoints with their early-start rasagiline 2 mg/day dose
[35]. They postulated that the results could be positive if
the rasagiline 2 mg/day dose was tested on more se-
verely affected patients at baseline [39]. However, this
could mean a higher drop-out rate especially in the pla-
cebo/active treatment group during the first phase of the
study which could confound the results. Questions re-
main that if the trial was extended further in a blinded-
manner during the second phase, whether the difference
in outcome between the delayed-start and early-start
treatment groups would diverge or converge.
Symptomatic benefits of MAOB inhibitors in early PD
when compared with other medications for PD
MAOB inhibitors provide a modest symptomatic benefit
in the treatment of early PD. The change in mean total
UPDRS score after 3 months of selegiline 10 mg/day
was −1.6 points in the DATATOP study [13], while the
change in mean score after 6 months of rasagiline 1mg/
day was +0.1 points in the TEMPO study [30]. The deteri-
oration in the UPDRS scores for the treatment groups in
Compensatory changes for dopamine loss in presymptomatic Parkinson disease
1. Increase in corticostriatal excitatory connections [52].
2. Selectively reduce the excitatory connections to the indirect pathway [53].
3. Increase in the synthesis and release of dopamine [54]. 
4. Reduce in synaptic dopamine active transporter [55]. 
5. Increase in postsynaptic D2 receptor levels [56,57].
6. Reduce the ability to release GABA in the striatopallidal indirect pathway [53].
7. Increase in the synaptic strength of GPe-STN connections [58]. 
8. Hyperactivity of subthalamic nucleus [59].
Figure 2 Compensatory changes for dopamine loss in pre-symptomatic Parkinson's disease. Abbreviations: GPe, globus pallidus pars
externa; GPi, globus pallidus pars interna; STN, subthalamic nucleus; SNc, substantia nigra pars compacta; GABA, gamma-aminobutyric acid. Solid
arrows: excitatory glutamatergic connections; Dot arrows: inhibitory GABAergic connections; Dash dot arrow: dopaminergic connections.
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placebo, indicating a symptomatic benefit of MAOB inhib-
itors. Although there are no direct comparisons as yet, the
symptomatic benefits of MAOB inhibitors were weaker
when compared to dopamine agonist or levodopa. The
change of mean motor UPDRS score was −4.5 points for
ropinirole, -3.4 points for pramipexole and −7.3 points for
levodopa after 6 months of treatment [40,41].Table 1 Pharmacology properties and therapeutic benefits of
Seleg





Adjunct to levodopa and treatment to motor complications Likely
- Levo
- Redu
Disease-modification InsuffiObstacles to clinical trials in disease-modification for PD
There are inherent problems with PD which may form
insurmountable barriers to disease-modifying strategies
in clinical trials. There are no consistently reliable bio-
logical or neuroimaging markers in PD. As yet, the diag-
nosis of PD is still made clinically. There are no similar
markers to correlate with disease progression. Its defin-
ition, progression and primary outcome measures areMAOB inhibitors in clinical use for Parkinson's disease
iline Rasagiline
daily 1 mg daily
wn [61] 36% [62]
rs [61] 0.6 – 2 hours [62]
hetamine like metabolites [61] Aminoindan [62]
ious [15] Efficacious [30,35]
efficacious [15] Efficacious [28,29]
dopa sparing effect - Levodopa sparing effect
ction in motor fluctuation - Reduction in motor fluctuation
cient evidence Insufficient evidence
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Furthermore, its clinical features are heterogeneous,
from tremor-predominant to akinetic-rigid forms, youn-
ger onset patients with more dystonic features, and older
onset patients with more dementia [42,43]. Its progres-
sion also varies between different patients, and mayTable 2 Major trials for selegiline and rasagiline
Selegiline
DATATOP 1993 [13]
Study design RCT selegiline vs. placebo
Participants 800 patients
Follow up period 2 years
End point Functional disability requiring levodopa




Study design RCT selegiline vs. placebo, as adjunct to
levodopa
Participants 116 patients
Follow up period 5 years
End point Increase in >50% of initial levodopa dose
Major finding Primary end point delayed in the
selegiline group
Conclusion Symptomatic benefit as adjunct to levodopa
Larsen 1999 [17]
Study design RCT selegiline vs. placebo, as adjunct to
madopar. 1 month wash out of selegiline at
the end of study period
Participants 163 patients
Follow up period 5 years
End point Levodopa requirement and deterioration of
UPDRS score
Major finding Lower levodopa requirement and UPDRS
score in the selegiline group
Conclusion Symptomatic benefit as adjunct to madopar
Possible disease-modifying effect
Palhagen 2006 [16]
Study design RCT selegiline vs. placebo, as adjunct
to levodopa
Participants 140 patients
Follow up period 7 years
End point Deterioration of UPDRS score
Major finding Slower disease deterioration in the
selegiline group
Conclusion Symptomatic benefit as adjunct to levodopadiffer within the same patient at different points in time
[44-46]. The UPDRS is inadequate to address the many
complexities associated with PD symptomatology. This
score is focused primarily on dopaminergic responsive
symptoms, and is poorly adapted to help define and
monitor non-motor features which are more disabling,Rasagiline
TEMPO 2004 [31]
Study design Randomized, delayed start trial rasagiline for
1 year vs. 6 months placebo then
6 months rasagiline
Participants 404 patients
Follow up period 1 year
End point Change in UPDRS score





Study design RCT rasagiline vs. placebo, as adjunct
to levodopa
Participants 472 patients with daily off time
Follow up period 26 weeks
End point Total daily off time
Major finding Less off time in the rasagiline group
Conclusion Symptomatic benefit as adjunct to levodopa
LARGO 2005 [29]
Study design RCT rasagiline vs. entacapone vs. placebo, as
adjunct to levodopa
Participants 687 patients with daily off time
Follow up period 18 weeks
End point Total daily off time
Major finding Less off time in the rasagiline group
Conclusion Symptomatic benefit as adjunct to levodopa
ADAGIO 2009 [35]
Study design Randomized, delayed start trial rasagiline for
72 weeks vs. 36 weeks placebo then
36 weeks rasagiline
Participants 1176 patients
Follow up period 72 weeks
End point Three hierarchical end points to indicate
significant disease-modification
Major finding Rasagiline 1 mg/day achieved all three
hierarchical end points, but not in 2 mg/day dose
Conclusion Possible disease-modifying effect
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prove the UPDRS and new diagnostic criteria for non-
motor features are being established in an effort to
address these concerns [47-49]. This task is made more
difficult considering that PD patients can have fluctua-
tions in motor and non-motor clinical features even
within the same day. Perhaps the most difficult issue is
that the cause or causes of PD are unknown. PD may
have heterogeneous etiologies and probably multiple
pathogenic pathways. Clinical trials using single or even
double agents designed to modify the course of a homoge-
neous disorder may well never achieve its aim. Con-
ducting clinical trials is expensive, especially when
combinations of therapies are tested for extended periods.
There is still no clear consensus on what constitutes a
disease-modifying therapy as there are many caveats to its
definition.
Potential benefits of early treatment in normalizing
compensatory mechanisms in PD
Disease-modifying therapy should intuitively have the
most impact at the earliest stages of the disease when
there are still functional neuronal networks to be pre-
served. Indirect evidence from the ELLDOPA (Earlier
versus Later Levodopa Therapy in Parkinson Disease)
[50], and TEMPO trials have shown that symptomatic
therapies started early in the disease may help to reduce
the severity in the latter stages of the disease compared
with a later start [34]. Schapira and Obeso had proposed
that compensatory changes in the basal ganglia circuit-
ries and thalamo-cortical projections occur in the earlier
stages of PD to maintain its physiological motor function
in response to a gradual deficit in striatal dopamine asso-
ciated with degeneration of the nigrostriatal pathway [51].
Compensatory changes can occur at the nigrostriatal
pathway and the basal ganglia circuit [52-59] (Figure 2).
They further proposed when the dopaminergic deficit in
PD surpasses the threshold of basal ganglia compensa-
tory mechanisms, motor symptoms develop associated
with hyperactivity in globus pallidum externa-subthalamic
nucleus-globus pallidum interna pathway and loss of
modulation for normal basal ganglia output. A major
feature of this basal ganglia imbalance is potentially
deleterious glutamatergic hyperactivity arising from the
subthalamic nucleus, pedunculopontine nucleus, intra-
laminar thalamic nucleus, and corticostriatal projection,
exacerbating excitotoxicity and other pathological me-
chanisms. Earlier restoration of the dopaminergic deficit
with early symptomatic treatment may restore this im-
balance to a more normal state, and reduce deleterious
pathological mechanisms which can exacerbate the pro-
gression of the disease. It is unclear whether early
symptomatic treatment is associated with long term
disease-modifying effects. Their hypothesis indicatesthat symptomatic and disease-modifying effects in clin-
ical trials are not mutually exclusive [60].
Conclusions
Tables 1 and 2 summarize the pharmacology properties,
therapeutic benefits and major trials for selegiline and
rasagiline. There is little to choose between selegiline and
rasagiline, although the latter does not have amphetamine-
like side effects which may cause appetite suppression and
insomnia. Unlike the laboratory evidence, there is cur-
rently no conclusive proof from existing clinical trials that
MAOB inhibitors have disease-modification effects on the
natural history of PD. Questions remain whether the re-
sults of the disease-modification trials reflect genuine
disease-modifying effects, or confounded by the limita-
tions of the clinical trials and the measures of efficacy.
However, the potential benefits of MAOB inhibitors with
little or well-tolerated side effects may be useful in some
patients with PD, especially in younger patients with
milder symptoms as monotherapy or as an adjunct to
levodopa.
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